Related Experiment Video

Updated: Aug 25, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway

Martha L Slattery1, Wade Samowitz, Michael Hoffman

  • 1Health Research Center and Department of Pathology, School of Medicine, University of Utah, 375 Chipeta Way, Suite A, Salt Lake City, UT 84108, USA mslatter@hrc.utah.edu

Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
|April 7, 2004
PubMed
Abstract

Insights

Aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) reduce colorectal cancer risk. Genetic variations in IRS1 and VDR genes interact with NSAID use, suggesting mechanisms beyond COX-2 inhibition may be involved.

Area of Science:

  • Oncology
  • Pharmacogenomics
  • Cancer Prevention

Background:

  • Aspirin and NSAIDs are known to reduce colorectal cancer risk.
  • Cyclooxygenase-2 (COX-2) inhibition is the presumed mechanism, but other pathways may be involved.
  • This study investigates the role of insulin-related pathways in the protective effects of aspirin/NSAIDs against colorectal cancer.

Purpose of the Study:

  • To explore the association between aspirin/NSAID use, insulin-related genetic pathways, and colorectal cancer risk.
  • To identify potential genetic modifiers of aspirin/NSAID efficacy in colorectal cancer prevention.
  • To investigate mechanisms of action beyond COX-2 inhibition.

Main Methods:

  • A case-control study was conducted with 1346 colon cancer cases, 1544 controls, 952 rectal cancer cases, and 1205 controls.
  • Genetic polymorphisms in five insulin-related pathway genes (VDR, IGF1, IGFBP3, IRS1, IRS2) were genotyped.
  • Interactions between NSAID/aspirin use and gene polymorphisms were analyzed in relation to colorectal cancer risk.

Main Results:

  • Aspirin and NSAID use was associated with decreased colorectal cancer risk, with NSAIDs showing slightly greater protection for rectal cancer.
  • Significant interactions were observed between IRS1 genotype and aspirin/NSAID use, particularly for the GG genotype and NSAID use.
  • Interactions between aspirin/NSAID use and VDR gene polymorphisms (SS or BB genotypes) were also significant, with NSAIDs reducing risk across all genotypes.

Conclusions:

  • The findings support the protective role of aspirin and NSAIDs in colorectal cancer prevention.
  • Interactions between aspirin/NSAID use and IRS1/VDR genotypes suggest non-COX-2-dependent mechanisms contribute to their protective effects.
  • Genetic variations in insulin-related pathways may influence individual responses to aspirin and NSAIDs for colorectal cancer risk reduction.

More Related Videos

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...